Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Breast Cancer Monthly Minutes

A small study suggests that in select patients with long-lasting disease stabilization, elective discontinuation of CDK4/6 inhibitors is feasible.
A large retrospective cohort population-based study demonstrated a disproportionate elevation of breast cancer–specific and all-cause mortality among African American women.
For the treatment of patients with HR-positive/HER2-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy.
CDK4/6 inhibitors were associated with improved outcomes in HR-positive/HER2-negative advanced metastatic breast cancer.
Study results suggest the potential of clinical development of estrogen receptor, CDK4/6, and AKT co-targeting strategies after progression on a CDK4/6 inhibitor and endocrine therapy combination, and in tumors showing high phospho-AKT levels.
CDK4/6 inhibitors combined with anti-HER2 agents in HER2-low expressing MBC cases warrant prospective evaluations.
Evidence from studies indicates that common genetic and epigenetic features of male and female breast cancer are not shared, but further studies are warranted.
Breast cancer survivors should be closely monitored and offered appropriate evidence-based treatment for fatigue, cognitive dysfunction, and sexual problems.
An analysis of racial minority groups treated for breast cancer demonstrates worse survival outcomes.
Breast cancer’s initiation, progression, and behavior may be affected by chronic inflammation.
Page 1 of 4
Results 1 - 10 of 40